Glenmark Pharmaceuticals on Tuesday announced a new randomised, open-label study to test the combined efficacy of two antiviral drugs Favipiravir and Umifenovir as a potential COVID-19 treatment strategy.
The two antiviral drugs have a different mechanism of action, and their combination may demonstrate improved treatment efficacy by effectively tackling high viral loads in patients during an early stage of the disease, said the pharma major in a statement.
Monika Tandon, Vice President and Head for Clinical Development Global Specialty and Branded Portfolio, said combining antiviral agents that have a good safety profile and act on different stages of viral life-cycle is an effective treatment approach to rapidly suppress initial high